Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: George Mc Geary who wrote (831)	2/24/2000 10:55:00 AM
From: Ian@SI	Respond to of 1321

George, I think the most important milestone is the FDA approval. Cdn approval would be nice but we've got about 1/10th the US population and probably 1/10th the AMD cases. Thus I don't expect much of a bump from Cdn approval. The FDA is probably vastly overloaded with all the huge breakthroughs now underway in the biotech sector. So it's tough to say how much better your Mar80s will do - that is a very short time between now and March 18th. With FDA approval, you're a genius. Without it, you just made a nice profit for a 4 week risk period. I've still seen nothing that justified that 2 or 3 hour selloff the other day. I just can't believe that a reiterate from an unknown had anything to do with it. Perhaps I'm overestimating the intelligence of the mutual fund managers holding QLT. Good luck. Ian.

To: George Mc Geary who wrote (831)	3/1/2000 11:05:00 PM
From: Ian@SI	Read Replies (1) \| Respond to of 1321

George, You very well may get your wish. QLT is expecting FDA approval early in 2Q2000. There are no major issues outstanding and no new issues have been raised. We should also see a series of press releases between now and the end of April when ARVO is held in Fort Lauderdale. Prior to that the 2 year results (not the details) for the TAP trial should be issued in a press release. Full enrollment has been achieved for all of the trials underway. Should see preliminary results (6 month checkpoint agreed to with FDA) for the Barrett's trial by 4Q. Several others will yield results in 3Q2000: Phase 2 Psoriasis study. Phase 2 NonMelanoma Skin Cancer study and the Rheumatoid Arthritis proof of concept. And their third Photodynamic drug is being readied for trials this year. All in all, looks like some exciting growth potential ahead for QLT. Ian.